Posted by AGORACOM
at 4:10 PM on Tuesday, November 19th, 2019
SPONSOR: Lomiko Metals LMR:TSX-V – A Canadian exploration-stage company discovered high-grade graphite at its La Loutre Property in Quebec and is working toward a Pre-Economic Assessment (PEA) that will increase its current indicated resource of 4.1 Mt of 6.5% Cg to over 10 Mt of 10%+ Cg through a 21 hole program at the Refractory Zone. Click Here For More Information
The Smartroad Gotland project will today install the first section of
the world’s first wireless electric road system (ERS) for trucks and
buses on public roads. ERS supports electric power transfer to vehicle
while in motion and have great potential to decarbonize the transport
sector and to increase energy efficiency with a reduced need of
batteries. Smartroad Gotland is supported and funded by the Swedish Road
Administration and is led by ElectReon AB, a Swedish subsidiary of the
Israeli company ElectReon Wireless. The goal of the project is to prove
that ElectReon’s technology is ready for commercialization and to
provide decision makers with knowledge necessary for large-scale ERS
deployment.
Wireless ERS is based on coils installed below the road surface and
transfer energy to a receiver that can be mounted on all types of
electric vehicles such as trucks, buses, vans, and passenger cars,
enabling them to charge on the go and use minimal batteries.
The installation deployment process is simple: a 10 cm deep trench is
created in the middle of the road lane in which copper coils embedded
in rubber are placed and then the road is repaved with asphalt.
Representatives from several countries are present on Gotland to
evaluate the process as they consider a future deployment of the
technology.
The Smartroad Gotland project will start operations early 2020 with
an electric truck and trailer. Before the summer the electric road will
also charge and power an electric bus. Throughout the three year long
project, the system performance and user experiences will be evaluated
together with RISE Research Institute of Sweden.
ElectReon has developed a unique technological design with a high
efficiency suitable for both dynamic and static charing. The solution
also includes a real-time communication system to ensure safety, access
control, and energy metering, and which also can support autonomous
vehicles. Thereby, the solution offers a smart and cost effective way of
enabling a transition towards electric road transportation without any
visual impacts or need for mechanical contact and heavy maintenance.
“Today marks a very important milestone based on thorough
preparations and a very dedicated team. A preparatory session was
conducted on the ElectReon test site in Israel a month ago to train the
team before this first deployment on public roads. I am glad that we are
progressing according to plan and are now ready for Swedish climate and
conditions.†– Håkan Sundelin, Project Manager, Smartroad Gotland
“We are very excited to deploy our technology for a real world
application for the first time after proving that it is fully functional
in our test site. As part of the process we are also shifting to mass
production of our coils on the way to full commercialization of our
technology.†– Oren Ezer, CEO, ElectReon Wireless
“We believe this technology has potential to become a standard for
roads in the future, and we want to use our skills to take it there. NCC
has experience from other ERS solutions that will benefit the
construction of the smart road in Gotland. The technology has shown
impressive results already.†– Stefan Hörnfeldt, affärschef eRoad, NCC
Infrastructure
How it works
The system consists of three key elements; the Coil transferring
energy to a Receiver on the vehicle and a Management Unit connected to
the grid controlling the process. The Management Unit is connected to
the electric grid and transfer energy to copper coils buried 8 cm below
the lane when a valid vehicle is exactly above. The energy is wirelessly
transferred from the coil to a receiver mounted underneath the vehicle.
The system makes sure only valid vehicles receives energy and keeps
track of how much in order to bill the right customer. A passenger car
needs one receiver and a 40-ton truck would use five, but utilizing the
same infrastructure.
Partners of the Smartroad Gotland project
Caverion, Dan transport, Eitech, Electreon AB, Flygbussarna, GEAB,
Gotland GPe Circuit AB, Gotlands Bilfrakt, Hutchinson, Matters Group,
Eksjö Maskin & Truck, Region Gotland, NCC, OSAB, RISE, Science Park
Gotland, Swedavia, Trafikverket, World Ecological Forum.
Posted by AGORACOM-JC
at 8:59 AM on Tuesday, November 19th, 2019
Signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc.
Transaction valued at USD$7.5Â million
NBS currently operates a 5,000 sq. ft. indoor cultivation facility and has been approved for expansion of up to 60,000 sq. ft of greenhouse space.
Property also includes an operating extraction facility and licensed and approved commercial kitchen.
This infrastructure is capable of manufacturing and bottling beverages and edibles and is currently used by NBS for both white label and branded product manufacturing.
TORONTO, Nov. 19, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that Bonfire Brands USA, a wholly owned subsidiary of NORTHBUD, has signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc. (“NBSâ€) (see June 25, 2019 press release) in a transaction valued at USD$7.5 million.
Nevada Botanical Science (NBS) is located in Reno, Nevada. NBS holds
Nevada State medical and adult use licenses for cultivation, extraction
and distribution. NBS operates an integrated cannabis operation located
on 3.2 acres of land within the Reno green zone industrial park. NBS
currently operates a 5,000 sq. ft. indoor cultivation facility and has
been approved for expansion of up to 60,000 sq. ft of greenhouse space.
The property also includes an operating extraction facility and licensed
and approved commercial kitchen. This infrastructure is capable of
manufacturing and bottling beverages and edibles and is currently used
by NBS for both white label and branded product manufacturing. Operated
by healthcare professionals, NBS has been primarily focused on the
Nevada State medical cannabis market. NBS currently manufactures and
sells award winning (Jack Herer Cup 2018) topical pain creams, balms and
lotions under the Trichomic medical brand.
This past year NBS launched a trial release of cannabis infused
cocktails under the brand “Happiest Hourâ€. Collaborating with local
craft beverage manufactures NBS released a variety of beverages
including Margarita, Pina Colada, Bloody Mary, Long Island Ice Tea and
Lemonade to select retailers in the state. To date retailer adoption and
reordering has been 100% and based on customer feedback, NBS will
increase production and distribution including additional retailers in
Las Vegas in 2020. NBS has also finished a successful trial launch of
its energy shot 1oz beverage containing 25mg of THC and 50mg of
Caffeine. The Company plans to run a second branded trial in early 2020.
Over the past three months NBS and NORTHBUD have been working together
in preparation for the release of NORTHBUD branded dried flower products
in Q4 2019 and a variety of infused and non-infused pre rolls.
“Subject to the finalizing of the previously announced acquisition of
the Qlora Group in California, the Company plans to establish a unified
product manufacturing and distribution platform within these two
important states,†said Justin Braune, President of Bonfire Brands USA.
“The license classes in California and Nevada allow for identical
activities and the Company has been in negotiation with multiple
potential JV partners who wish to leverage this unique platform. Being
one of the few multi state operators with operations in both states will
allow us to offer turnkey solutions to prospective partners moving
forward.â€
Transaction Terms
The transaction (the “Transactionâ€) is structured as an asset
purchase agreement whereby in exchange for the purchase of all of the
securities and assets of NBS, NORTHBUD is paying a total of
USD$7,500,000 as follows:
Cash payment of USD$500,000 (paid in full);
Approximately USD$1 million in convertible shares of Bonfire Brands USA (6,500,000 “convertible sharesâ€); and
A USD$6,000,000 interest bearing promissory note.
The convertible shares may be exchanged on a 1-1 basis with common
shares of NBUD at the discretion of the shareholder. At the time of
signing, the converted value of these securities was equal to
USD$1,000,000. All applicable U.S. and Canadian regulatory holds shall
apply upon conversion.
As per the terms of the agreement NBS will allocate pro rated
ownership of assets in NBS and all associated licenses to Bonfire Brands
USA throughout the re-payment period, subject to state approval.
Bonfire Brands and NBS have agreed to an operations and management
arrangement allowing Bonfire to assume operational control, begin
integration and driving revenue immediately.
“The NORTHBUD and Bonfire Brands USA team are extremely proud to have
finalized this agreement making the state of Nevada our strategic entry
point into the U.S. legal cannabis market,†said Ryan Brown, CEO of
NORTHBUD. “We are equally proud of the structure of the deal and how it
minimizes shareholder dilution while allowing our team to begin
integration and operations with a focus on immediate revenue growth in
one of the most sought-after adult use markets in North America. Our
team has been looking at acquisitions in Nevada for over two years
before finding the right fit. The Nevada market is considered one of
the largest and most profitable in North America with recreational sales
of USD$580 million in the first full year of legalization* (2017 Nevada
Dept. of Taxation).â€
The securities of the Company have not been and will not be
registered under the United States Securities Act of 1933, as amended
(the “U.S. Securities Actâ€) or any state securities
laws. Accordingly, the securities of the Company may not be offered or
sold within the United States unless registered under the U.S.
Securities Act and applicable state securities laws or pursuant to an
exemption from the registration requirements of the U.S. Securities Act
and applicable state securities laws. This news release does not
constitute an offer to sell or a solicitation of an offer to buy any of
the securities of the Company in any jurisdiction in which such offer,
solicitation or sale would be unlawful.
The Transaction is a significant acquisition but will not result in a
“Fundamental Change†pursuant to the policies of the CSE. NORTHBUD will
be preparing the necessary corporate and securities filings in order to
secure the required approvals for the Transaction.
The parties have agreed to pay USD$187,500 in broker/finder fees to
arm’s length parties on a prorated basis connection with the closing of
the Transaction.
The closing of the Transaction is conditional on the receipt by the
parties of applicable corporate and regulatory approvals, including that
of the CSE.
About Nevada Botanical Science, Inc.
Founded by a group of northern Nevada physicians and healthcare
professionals who believe in the promise of medical cannabis, Nevada
Botanical Science has developed a world class cannabis production,
research and development facility in Reno’s Washoe County. Its work and
commitment are fully in compliance with the Hippocratic Oath as well as
Nevada statute. Nevada Botanical Science is dedicated to ensuring the
highest measure of safety, governance and stewardship for its patients,
employees and the community it serves.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros
MMP Inc., is pursuing a licence under The Cannabis Act. The Company has
built a state-of-the-art purpose-built cannabis production facility
located on 135 acres of Agricultural Land in Low, Quebec, Canada.
NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA
has acquired Nevada Botanical Science, Inc. a world class cannabis
production, research and development facility with 5,000 sq. ft. of
indoor cultivation in Reno’s Washoe County. Nevada Botanical Science
holds medical and adult use licenses for cultivation, extraction and
distribution. Bonfire Brands USA has entered into an agreement to
acquire assets in Salinas, California.
Neither the Canadian Securities Exchange (the “CSEâ€) nor its
Regulation Services Provider (as that term is defined in the policies of
the CSE) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements Certain statements and
information included in this press release that, to the extent they are
not historical fact, constitute forward-looking information or
statements (collectively, “forward-looking statementsâ€) within the
meaning of applicable securities legislation. Forward-looking
statements, including those identified by the expressions “anticipateâ€,
“believeâ€, “planâ€, “estimateâ€, “expectâ€, “intendâ€, “mayâ€, “should†and
similar expressions to the extent they relate to the Company or its
management. This press release contains forward- looking statements
including those relating to the entering into of the Definitive
Agreement and closing of the Transaction with Nevada Botanical Science,
Inc. Forward-looking statements are based on the reasonable assumptions,
estimates, analysis and opinions of management made in light of its
experience and its perception of trends, current conditions and expected
developments, as well as other factors that management believes to be
relevant and reasonable in the circumstances at the date that such
statements are made, but which may prove to be incorrect.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the Company to differ materially from any
future results, performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risk factors included in the Company’s final long form
prospectus dated August 21, 2018, which is available under the
Company’s SEDAR profile at www.sedar.com.
Accordingly, readers should not place undue reliance on any such
forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which such statement is made. New factors
emerge from time to time, and it is not possible for the Company’s
management to predict all of such factors and to assess in advance the
impact of each such factor on the Company’s business or the extent to
which any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statements to reflect information, events, results,
circumstances or otherwise after the date hereof or to reflect the
occurrence of unanticipated events, except as required by law including
securities laws. This news release does not constitute an offer to sell
or a solicitation of any offer to buy any securities of the Company.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT: North Bud Farms Inc. Edward Miller VP, IR & Communications Office: (855) 628-3420 ext. 3 [email protected]
Posted by AGORACOM-JC
at 5:37 PM on Monday, November 18th, 2019
SPONSOR: NORTHBUD (NBUD:CSE)
Sustainable low cost, high quality cannabinoid production and
procurement focusing on both bio-pharmaceutical development and
Cannabinoid Infused Products. Learn More.
THC-infused edibles and CBD-infused edibles
When cannabis is ingested, the THC is metabolized by the liver
With edibles coming to brick-and-mortar shops in mid-December, users are looking to get high without the smoke.
But when choosing edibles, users will want to pay attention to
whether the product has CBD or THC, two compounds with very different
effects.
CBD
CBD, the non-psychoactive component within cannabis has been widely
touted for its medical benefits to help people with, among other
conditions, chronic pain. The World Health Organization (WHO) reports
CBD is not physically addictive.
By comparing those administered doses of active CBD to those given as
a placebo, researchers said that “while the number of studies is
limited, the evidence from well-controlled human experimental research
indicates that CBD is not associated with abuse potential.â€
CBD leads to slower effects that aren’t psychoactive in
nature — meaning they aren’t the effects you see portrayed in pop
culture.
The effects from CBD will be tame and mellow compared to its
psychoactive opposite, THC. Most medical cannabis includes CBD rather
than THC, with CBD already available in capsule form in legal stores.
THC
When most people think of cannabis’ effects, they think of THC. Many
of the new cannabis products slated to enter stores in mid-December will
focus on THC.
When cannabis is ingested, the THC is metabolized by the liver,
transforming itself into 11-hydroxy-THC. This metabolite is up to four
times faster in crossing the blood-brain barrier than average THC, and
is why edibles are associated with intense, vivid and longer-lasting
experiences.
THC normally gets pointed at as the compound that creates the potential for withdrawal symptoms among some heavy users.
An evidence brief compiled by the Canadian Public Health Association (CPHA) states that “cannabis is addictive, though not everyone who uses it will develop an addiction.â€
While using cannabis oil or edibles with THC, users may get addicted
or experience habit-formation. Products that only include CBD don’t
appear to become addictive.
Posted by AGORACOM
at 12:25 PM on Monday, November 18th, 2019
VERT: v –
Vertical Exploration and Venturevest Realty Partners LLC have signed a non- binding Letter of Intent (LOI) to enter into discussions regarding a secured Note Facility up to a maximum amount of $20 million CAD to support the multi-phased development of the St-Onge Wollastonite Deposit.
A staged credit facility allowing Vertical to move forward with four distinct phases of St-Onge development, first establishing the initial quarry style permitting and production phase through to the mining and final processing plant stage.
What is Wollastonite?
Wollastonite is a chemically simple mineral named in honor of English mineralogist and chemist Sir W.H. Wollaston (1766–1828). It is composed of calcium (Ca) and silicon and oxygen (SiO2, silica) with the chemical formula CaSiO3. Although much wollastonite is relatively pure CaSiO3, it can contain some iron, magnesium, manganese, aluminum, potassium, sodium, or strontium substituting for calcium in the mineral structure. Pure wollastonite is bright white; the type and amount of impurities can produce gray, cream, brown, pale-green, or red colors.
Wollastonite’s Many Uses
Cannabis Research:
Wollastonite has already many well-known benefits in agriculture
Testing in a controlled way for the use in the cannabis industry.
Possibly the first in the industry to do trials.
Engaged AGRINOVA for Wollastonite Research and Development
Entered into a
Distribution Agreement with AREV Brands, where Vertical will supply its
St-Onge wollastonite to AREV for direct distribution to both small-scale
craft growing operations and potentially larger-scale Health Canada
approved companies directly involved in growing and processing cannabis
and hemp.
Testing of Vertical’s St-Onge wollastonite on a range of important agricultural end uses will also be conducted
Became a member of the International Fertilizer Industry Association
(IFA), as part of its ongoing efforts to promote and strategically
market it’s world-class St-Onge wollastonite to a range of potential
end-users.
Major Demand in Ceramics Industry:
Combination of high brightness and low gas release of Wollastonite when heated creates demand
Brilliant whiteness of importance to coatings and filler markets
Wollasatonite applications are endless
An industrial mineral comprised
chemically of calcium, silicon and oxygen. Its molecular formula is
CaSiO3 and its theoretical composition consists of 48.28% CaO and 51.72%
SiO2.
St. Onge Wollastonite Deposit 2019
Twenty-three (23) drill holes totaling 1,784.0 metres were completed
Twenty (20) drill holes intersected high-grade wollastonite zones,
confirming excellent continuity and correlation with the thickly
mineralized zones intersected by previously reported historical drill
holes.
Sixteen (16) drill holes intersected high-grade wollastonite zones
right up until the end of the hole, which are all open at depth.
A total of 1,107.5 meters of high-grade wollastonite mineralized
core length was intersected, representing approximately 62% of all
drilled core length.
Posted by AGORACOM
at 12:15 PM on Monday, November 18th, 2019
Has now completed the drilling portion of the 2019 Regal exploration
program at the Regal property, 1,846 meters of diamond drilling was
completed in 21 holes.
22 samples collected from the Black Jacket and Allco areas of the
Regal property located approximately 35 km northeast of Revelstoke, BC.
The majority contained bonanza grade silver, zinc, and lead with many samples reaching assay over-limits.
Further assaying of over-limits has been initiated, results will be reported once received.
Property History & Background
The property hosts numerous mineral occurrences including the following past-producing mines:
Snowflake and Regal Silver (Stannex/Woolsey) Mines
The Snowflake and Regal Silver mines were two former producing mines
that operated intermittently during the period 1936-1953. The last
significant work on the property took place from 1967-1970, when Stannex
Minerals completed 2,450 meters of underground development work and a
feasibility study, but did not restart mining operations. In 1982,
reported reserves were 590,703 tonnes grading 71.6 grams per tonne
silver, 2.66 per cent lead, 1.26 per cent zinc, 1.1 per cent copper,
0.13 per cent tin and 0.015 per cent tungsten (Minfile No. 082N 004 –
Prospectus, Gunsteel Resources Inc., April 29, 1986). It should be noted
that the above resource and grades, although believed to be reliable,
were prepared prior to the adoption of NI43-101 and are not compliant
with current standards set out therein for calculating mineral resources
or reserves.
ALLCO Silver Mine
The Allco Silver Mine is situated 6.35 Kilometers northwest of the
above described Snowflake/Regal Mine(s) and is also part of the Affinity
claim group.
The Allco Silver Mine operated from 1936-1937 and produced 213 tonnes
of concentrates containing 11 troy ounces of gold (1.55 g/t), 11,211
troy ounces of silver (1,637 g/t) and 173,159 lbs of lead (36.9%).
Airborne Geophysics to Guide Future Exploration
An extensive airborne geophysics survey conducted by Geotech Ltd of
Aurora, Ontario, for Northaven Resources Corp. in 2011, identified four
well defined high potential linear targets correlating with the same
structural orientation as the Allco, Snowflake and Regal Silver mines.
Northaven also reported that the mineralogy and structural orientation
of the Allco, Snowflake and Regal Silver appeared to be similar to that
of Huakan’s J&L gold project located to the north, and on a similar
geophysical trend line. The J&L is reportedly now one of western
Canada’s largest undeveloped gold mineral resources.
After completing the airborne survey, Northaven failed in financing
their company and conducting further exploration on the property and
subsequently forfeited the claims without any of the follow up work ever
being completed. Affinity Metals is in the fortunate position of
benefitting from this significant and promising geophysics data and
associated targets.
The aforementioned Northaven airborne geophysical survey conducted at
a cost of $319,458.95 in August of 2011 is described in The BC Ministry
of Energy, Mines and Petroleum Resources Assessment Report #33054. The
results of the survey are competently explained and illustrated by
professionals on You Tube at: https://www.youtube.com/watch?v=GX431eBY_t0
FULL DISCLOSURE: Affinity Metals is an advertising client of AGORA Internet Relations Corp
Posted by AGORACOM
at 11:28 AM on Monday, November 18th, 2019
A 3D Induced Polarization (IP) geophysical survey on its Tabasquena project in Zacatecas, Mexico has outlined a significant continuous chargeability anomaly.
This anomaly now has an east-west width of approximately 400 to 500 metres and an apparent strike length of over 1000 metres.
The anomaly remains open to the north and to the south and at depth.
Drilling to commence once the IP survey has been completed.
The
chargeability anomaly is approximately 250 metres below historical
mining and was designed for 500 to 550 metres of vertical depth
investigation.
The IP data also clearly shows that the large polarisable body/target
is apparently quickly deepening northward and getting closer to surface
southward. The IP anomaly starts at around 100 metres below the past
drill hole intersections that contained widespread gold and silver
mineralization in epithermal veins.
Tabasquena
Previous drilling found a network of veins with widespread gold and silver mineralization.
The
first phase geophysical survey revealed a large chargeability anomaly
right below these veins and is getting nearer to the surface as it
trends south.
Geophysical advisor described the anomaly as ‘quite remarkable in its size and continuity.
Advance is in a region with very large mines, including the El Coronel open pit, 12 miles to the south of Tabasquena.
Posted by AGORACOM
at 4:43 PM on Friday, November 15th, 2019
SPONSOR: Lomiko Metals LMR:TSX-V – A Canadian exploration-stage company discovered high-grade graphite at its La Loutre Property in Quebec and is working toward a Pre-Economic Assessment (PEA) that will increase its current indicated resource of 4.1 Mt of 6.5% Cg to over 10 Mt of 10%+ Cg through a 21 hole program at the Refractory Zone. Click Here For More Information
New research by engineers at the University of Illinois combines
atomic-scale experimentation with computer modeling to determine how
much energy it takes to bend multilayer graphene—a question that has
eluded scientists since graphene was first isolated. The findings are
reported in the journal Nature Materials.
Graphene—a single layer
of carbon atoms arranged in a lattice—is the strongest material in the
world and so thin that it is flexible, the researchers said. It is
considered one of the key ingredients of future technologies.
Most of the current research on graphene
targets the development of nanoscale electronic devices. Yet,
researchers say that many technologies—from stretchable electronics to
tiny robots so small that they cannot be seen with the naked eye—require
an understanding of the mechanics of graphene, particularly how it
flexes and bends, to unlock their potential.
“The bending stiffness of a material is one of its most fundamental mechanical properties,” said Edmund Han, a materials science
and engineering graduate student and study co-author. “Even though we
have been studying graphene for two decades, we have yet to resolve this
very fundamental property. The reason is that different research groups
have come up with different answers that span across orders of
magnitude.”
The team discovered why previous research efforts disagreed. “They
were either bending the material a little or bending it a lot,” said
Jaehyung Yu, a mechanical science and engineering graduate student and
study co-author. “But we found that graphene behaves differently in
these two situations. When you bend multilayer graphene a little, it acts more like a stiff plate or a piece of wood. When you bend it a lot, it acts like a stack of papers where the atomic layers can slide past each other.”
“What is exciting about this work is that it shows that even though everyone disagreed, they were actually all correct,” said Arend van der Zande, a professor of mechanical science and engineering and study co-author. “Every group was measuring something different. What we have discovered is a model to explain all the disagreement by showing how they all relate together through different degrees of bending.”
To make the bent graphene, Yu fabricated individual atomic layers of
hexagonal boron nitride, another 2-D material, into atomic-scale steps,
then stamped the graphene over the top. Using a focused ion beam, Han
cut a slice of material and imaged the atomic structure with an electron microscope to see where each graphene layer sat.
The team then developed a set of equations and simulations to
calculate the bending stiffness using the shape of the graphene bend.
Graduate student Edmund Han, left, professor Elif
Ertekin, graduate student Jaehyung Yu, professor Pinshane Y. Huang,
front, and professor Arend M. van der Zande have determined how much
energy it takes to bend multilayer graphene – a question that has long
eluded scientists. Credit: Stephanie Adams
By draping multiple layers of graphene over a step just one to five
atoms high, the researchers created a controlled and precise way of
measuring how the material would bend over the step in different
configurations.
“In this simple structure, there are two kinds of forces involved in
bending the graphene,” said Pinshane Huang, a materials science and
engineering professor and study co-author. “Adhesion, or the attraction
of atoms to the surface, tries to pull the material down. The stiffer
the material, the more it will try to pop back up, resisting the pull of
adhesion. The shape that the graphene takes over the atomic steps
encodes all the information about the material’s stiffness.”
The study systematically controlled exactly how much the material bent and how the properties of the graphene changed.
“Because we studied graphene bent by different amounts, we were able
to see the transition from one regime to another, from rigid to flexible
and from plate to sheet behavior,” said mechanical science and
engineering professor Elif Ertekin, who led the computer modeling
portion of the research. “We built atomic-scale models to show that the
reason this could happen is that the individual layers can slip over
each other. Once we had this idea, we were able use the electron
microscope to confirm the slip between the individual layers.”
The new results have implications for the creation of machines that
are small and flexible enough to interact with cells or biological
material, the researchers said.
“Cells can change shape and respond to their environment, and if we want to move in the direction of microrobots or systems that have the capabilities of biological systems, we need to have electronic systems that can change their shapes and be very soft as well,” van der Zande said. “By taking advantage of interlayer slip, we have shown that the graphene can be orders of magnitude softer than conventional materials of the same thickness.”
Secured New Health Canada Device Clearance and Exclusive Canadian Sales Rights for US Medical ECG Device Manufacturer Read More
Entered into an exclusive sales and marketing agreement for the GEMS™ Sirona with California-based Datrix LLC
Under the multi-year, renewable agreement, CardioComm assumes the
role of exclusive Canadian distributor of the Datrix ECG recorders under
the GEMS™ Sirona brand device.
Secured Newest US and Canadian Medical Device 13485:2016 MDSAP Certification Read More
Completed its ISO 13485:2016 certification in compliance with the
Medical Device Single Audit Program, a mandatory requiment under Health
Canada and accepted as an equivalent quality management certification by
the USA Food and Drug Administration.
Announced ECG Services Integration and Co-Marketing Agreement with California-Based BodiMetrics LLC Read More
GEMS™ Universal will be available under two subscription models:
$6 US per month with one free ECG interpretation included; and,
$69 US per year with 12 free ECG interpretations that may be requested any time during the one year subscription.
Company Accolades
FULL DISCLOSURE: CardioComm Solutions Inc. is an advertising client of AGORA Internet Relations Corp.
Posted by AGORACOM
at 8:45 AM on Friday, November 15th, 2019
Successfully building BioPharma pipeline in high-value indications
Company plans to advance IND-cleared program into a Phase 1 study in a metabolic disease indication in early 2020
Strategic corporate shift to fully focus on BioPharma Division unlocks opportunities for non-dilutive capital to fund pipeline
Applied BioSciences Corp.
(OTCQB:APPB) (“Applied” or the “Company”), today announced its financial
results for the second quarter Fiscal Year 2020 ended September 30,
2019. The Company also provided an update on its corporate and clinical
progress.
“We continue to push forward on all fronts as we work to establish
Applied as a leader in the development and commercialization of novel,
science-driven, synthetic endocannabinoid therapeutics /
biopharmaceuticals and impact areas of significant unmet need,”
commented Dr. Raymond Urbanski, Chief Executive Officer of Applied.
“Over the course of the past quarter, we have made notable strides on
the corporate and clinical front and remain diligent in working to drive
value for all stakeholders.”
“We continued to build out our BioPharma division and have
established a Scientific Advisory Board of leading experts in the
endocannabinoid space. We were pleased to have welcomed our inaugural
members Judith Korner, M.D. and Patricia Reggio, Ph.D., who will play an
integral role as we look to optimize our therapeutic pipeline and look
to make additional appointments in the near term to help drive this
business unit forward. Additionally, we have continued to execute on our
robust business development initiatives and remain in late-stage
discussions to in-license our product candidates that we believe have
the potential to address a number of areas with significant unmet need.
In tandem, we continue to remain opportunistic in accessing the
necessary non-dilutive funding and capital through strategic investments
from which we believe will provide us with the foundation and momentum
to move forward.”
Applied BioPharma: developing
science-driven synthetic cannabinoid therapeutics that satisfy unmet
medical needs and continue to drive innovation in the endocannabinoid
space.
The Applied BioPharma division is focused on the development and
commercialization of novel therapeutics that target the endocannabinoid
system (ECS).
Applied Biopharma has to date developed partnerships with leading
academic and research institutions and has exclusively licensed
patented, synthetically derived small molecule candidates which target
the ECS G-protein coupled receptors (GPCRs) e.g., the cannabinoid
receptor 1 and cannabinoid receptor 2, for the treatment of metabolic
diseases (type 2 diabetes, obesity, fatty liver disease) and
inflammation (pulmonary inflammation, optic nerve inflammation following
traumatic brain injury and ischemic/reperfusion injury such as acute
kidney injury post-transplant and acute myocardial infarction (heart
attack).
The Company’s growing pipeline is comprised of selective CB1 and CB2
agonist, inverse agonist and antagonists utilizing multiple scaffolds
and state-of-the-art medicinal chemistry across several academic centers
and institutions.
Applied expects to advance the first of its preclinical programs into open INDs in 2020.
ABP-1902, its lead CB2 agonist, intended for mitigating the deleterious effects of ischemic-reperfusion injury.
ABP-1901, its lead CB2 inverse agonist, which has demonstrated
effectiveness in limiting or reversing damage due to neuroinflammation.
Applied expects to advance the first of its clinical programs into a Phase 1 study in early to mid-2020.
The Company is actively advancing and seeking additional in-license
opportunities with the goal of developing an industry-leading pipeline
of endocannabinoid system-targeted drug candidates that address
significant unmet needs across a wide range of therapeutic areas.
Applied Products: portfolio
of consumer, animal health, women’s health and sports medicine of
hemp-derived, THC-free, pharmaceutical grade CBD isolates and
distribution products, all of which ship to the majority of U.S., as
well as to multiple non-U.S. countries.
The Applied Products business unit is focused on maximizing top-line
revenue through selective investments in product lines and marketing
campaigns (increase share-of-voice), continually reevaluating the
endocannabinoid Health & Wellness environment for opportunities and
developing and implementing a nutraceutical strategy.
Applied Products has seen a modest year-over-year increase in top
line revenue. At this time the Board, with the understanding that to be
successful in the lucrative yet dynamic and very competitive consumer
CBD space would require significant resource and capital allocations, is
evaluating various strategic options for this business unit.
Trace Analytics, Inc:
Applied’s majority owned subsidiary scalable analytics
cannabis/cannabinoid laboratory poised to meet the demands for mandated
regulatory cannabis/cannabinoid testing.
In July 2019, Trace Analytics was contracted for services with the
Washington State Department of Agriculture (WSDA). This contract
includes testing Industrial Hemp samples and include percentage testing
for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta
9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of
certain cannabinoids are below Federal limits.
Applied is currently in late-stage discussions for a strategic transaction, expected to close by year end.
Upcoming Milestones Expected to Drive Value
Finalize the in-licensing of product candidates to build pipeline for the Applied BioPharma division.
Closing on the sale of Trace Analytics leading to the infusion of non-dilutive capital into the company.
Finalize and execute on the strategic options for Applied Products.
Successfully execute overall strategy of the Company and business development efforts.
Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company.
Uplist to a National Exchange.
Summary of Financial Results for Second Quarter FY2020 Ended September 30, 2019
For the quarter ended September 30, 2019, the Company reported net
loss of approximately $777,746 or net loss per diluted share of $0.06,
compared to a net loss of approximately $110,423 or a net loss per
diluted share of $0.01, for the quarter ended September 30, 2018.
The Company reported revenues from Applied BioSciences’ CBD product
lines was $169,654 and $59,400 during the six months ended September 30,
2019 and 2018, respectively. The increase reflects higher sales across
all of the Company’s CBD brand product lines, most notably in its
topical products, combined with expansion into sales of bulk hemp seed
and raw CBD. Service revenue resulting from the Company’s lab testing is
attributed solely to the acquisition of Trace Analytics in January
2019, and totaled $286,077 for the six months ended September 30, 2019.
General and administrative expenses increased $519,140 to $707,192
for the three months ended September 30, 2019 as compared to $188,052
for the three months ended September 30, 2018. The increase was mainly
attributable to the acquisition of Trace Analytics and addition of our
Applied BioPharma subsidiary, with general and administrative expenses
for the remainder of the Company.
The Company ended the quarter with $73,412 in cash and cash
equivalents. The Company is actively evaluating opportunities to fund
continued growth in its products and services revenue along with planned
business development activities for Applied BioPharma and anticipates
closing a financing by the end of first quarter Fiscal Year 2020.
About Applied BioSciences Corp.
Applied BioSciences is a vertically integrated company focused on the
development and commercialization of novel, science-driven, synthetic
cannabinoid therapeutics / biopharmaceuticals that target the
endocannabinoid system to treat a wide-range of diseases across multiple
therapeutic areas. We also deliver high-quality consumer and OTC
THC-free CBD products that promote overall health and wellbeing as well
as state-of-the-art testing and analytics capabilities to our customers.
For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.
Posted by AGORACOM
at 2:30 PM on Thursday, November 14th, 2019
SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info
The National Community Pharmacists Association (NCPA) has launched a new resource for pharmacists looking to understand and purchase reliable cannabidiol (CBD) products, called the NCPA CBD Source.
The online resource features CBD products that have been tested for concentrations of all cannabinoids, including CBD and tetrahydrocannabinol (THC), by an independent, third-party lab. The site also features experts that pharmacists can contact with questions regarding buying, selling, and marketing. In addition, pharmacists will be able to evaluate each company included in the resource, as well as see each company’s products.
CBD products have exploded in recent months following the Hemp Farming Act of 2018, which removed hemp from the list of Schedule I controlled substances. According to a statement from NCPA, the United States CBD industry grew by nearly 40% in 2017, and is expected to reach $22 billion by 2024.
CBD can help relieve pain and inflammation resulting from chronic illnesses, as well as boost the immune system, and these effects have led to a flood of patient interest.
“Many pharmacies are deciding to sell CBD products because of the patient demand and because, as the medication expert, they can serve as the source of truth,†said NCPA CEO B. Douglas Hoey, RPh, MBA.
Carter High, PharmD, of Best Value Rhome Pharmacy, said he plans on using the service to bolster the knowledge and products that he already trusts. CBD products are new to the pharmacy wheelhouse, High said, and he gets many phone calls with sales pitches from various CBD companies.
“It gets a little confusing as to whether or not they’re just talking a really good sales pitch, or if they really do have a genuine product,†High said.
High said it’s important for pharmacists to make sure they understand the uses and mechanisms of CBD products, but that this can be challenging given the crowded marketplace.
“Understanding just how CBD affects the body is a very good avenue for a pharmacist to delineate themselves as a knowledge expert on a new upcoming way of how to help patients out,†High said. “A marketplace such as [NCPA CBD Source] fills a very big gap that was missing, and helps from an efficiency standpoint at the store level.â€
While he is excited to use the resources provided, High did emphasize that it doesn’t relieve pharmacists of the responsibility to ensure that the products are reliable, safe, and right for each patient. It does, however, help reassure pharmacists that the decisions they are making are the right ones, he added.
REFERENCE
NCPA, PRS Launch First-of-its-Kind “CBD Source†Tool for Pharmacists
